Markets :: Specialty Chemicals :: Personal Care
Novozymes’ First-Half Ebitda Rises 11% Despite Market Uncertainty
7:08 AM MDT | August 11, 2011 | Alex Scott
Novozymes, a biotech firm, says its Ebitda for the first half of the year increased 11% to DK1.6 billion ($306 million) on sales up 9% to DK5.3 billion. All expectations for full-year 2011 are maintained, the company says. “l'm satisfied with the half-year results, and although we're seeing increasing general uncertainty concerning the global economic situation and increased volatility in our end markets, we’re able to maintain our sales and earnings growth guidance for the full year,” says Steen Riisgaard, president and CEO. Sales...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee